Corporate Profile
Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative oral drugs for patients with serious diseases and disorders, such as obesity and insomnia. We have a broad pipeline of drug candidates, both proprietary and partnered. Our lead proprietary drug candidate, lorcaserin hydrochloride, is intended for the treatment of obesity and is being evaluated in a Phase 3 clinical program.Featured Report
2007 Interactive Annual Report
Stock Information
| Ticker | ARNA | Exchange | NASD |
|
|
| Last Price | 3.31 | Change | 0.10 
|
||
| Open | 3.24 | Previous Close | 3.21 | ||
| Day High | 3.32 | Day Low | 3.24 | ||
| 52-Week High | 9.32 | 52-Week Low | 2.70 | ||
|
Quotes delayed at least 20 minutes. Information provided by eSignal.
|
|||||
Recent News
Oct 30, 2008
Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Oct 29, 2008
Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
Events & Presentations
There are no upcoming events available at this time.
Receive Email Alerts
The stock information, SEC filings and press releases included on this website are not provided by Arena Pharmaceuticals, Inc. but by a third-party. Such information is not intended for trading purposes. Arena Pharmaceuticals, Inc. does not guarantee the accuracy or completeness of this information and is not liable in any way whatsoever for any delays, inaccuracies, errors in, or omissions of any such information, or for any actions taken in reliance on this information, or for any damages arising there from.
